37.68MMarket Cap-2.58P/E (TTM)
0.980High0.860Low141.07KVolume0.880Open0.880Pre Close127.93KTurnover1.39%Turnover RatioLossP/E (Static)39.55MShares1.90052wk High-2.15P/B9.68MFloat Cap0.46352wk Low--Dividend TTM10.16MShs Float22.155Historical High--Div YieldTTM13.64%Amplitude0.463Historical Low0.906Avg Price1Lot Size
MiNK Therapeutics Stock Forum
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced data from two poster pres...
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
MiNK Therapeutics presented new data at SITC 2024 showcasing their iNKT cell therapy programs. Their lead therapy agenT-797, alone or combined with anti-PD-1, demonstrated durable disease control in heavily pretreated patients. When combined with bispecific engagers targeting MUC16, HER2, Claudin 18.2, and DLL3, it showed enhanced T-cell activation and...
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
MiNK Therapeutics (NASDAQ: INKT) announced two poster presentations at the Society for Immunotherapy of Cancer's 29th Annual Meeting in Houston, Texas, from November 6-10, 2024. The presentations will showcase new preclinical data from MiNK's iNKT cell programs, agenT-797 and PRAME-TCR.
The first presentation, titled 'AgenT-797 cell therapy can be combined with next-generation immune checkpo...
MiNK Therapeutics, Inc. (NASDAQ: INKT), a company in the biopharmaceutical sector, has announced an essential milestone in its quest to revolutionize cancer treatment. With a focus on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases, MiNK has...
MiNK Therapeutics Shares Are Trading Higher After the Company Announced Plans to Sell Securities in a Private Placement Financing for $5.8 Million. The Financing Is Earmarked for Accelerating Its MiNK-215 Clinical Trials
NEWS
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
CEO bought a lot
No comment yet